Daewoong Pharmaceutical and HanAll Biopharma said they will jointly invest in Vincere Biosciences, a Parkinson's disease drug development company based in Cambridge, Mass.With this investment, the three companies will explore opportunities to collaborate on the development of new treatments for Park
Kukje Pharm said Monday that it has signed an agreement with Eyegene to co-develop EG-Mirotin, the world's first treatment for non-proliferative diabetic retinopathy.According to Kukje, EG-Mirotin is a new-concept biological drug that treats diabetic retinopathy by relieving symptoms of recurrent sw
Bukwang Pharmaceutical has decided to withdraw its license for Fra-Cut Inj., a generic version of Mitsubishi Tanabe Pharma’s amyotrophic lateral sclerosis (ALS) treatment, Radicut (edaravone).That comes a year after the Ministry of Food and Drug Safety approved the drug.The ministry announced Monday
Hanmi Pharm said Monday its investigational drug, which failed to prove effectiveness in rheumatoid arthritis clinical trials, demonstrated efficacy against diffuse large B-cell lymphoma (DLBCL).The company said it disclosed the interim results from the phase 2 clinical trials of three-drug combinat
Minjuvi, a treatment for diffuse large B-cell lymphoma (DLBCL) imported by Handok, won marketing approval on Monday. The Ministry of Food and Drug Safety (MFDS) announced that it has approved Minjuvi (tafasitamab), an orphan drug used to treat DLBCL.DLBCL, one of the most common lymphomas, is a rapi
The five-month technology theft dispute between Algocare and Lotte over a nutrient dispenser product has reached an agreement, with Lotte Healthcare withdrawing the launch of the product.On Wednesday, the National Assembly held a meeting on the Prevention and Recovery Support for Start-up Technology
BOSTON, Mass. -- By Kim Chan-hyuk/Korea Biomedical Review correspondent -- A Korean pharmaceutical company has set its name engraved in Boston, Mass., a mecca for the global bio industry. The company is Yuhan USA, Yuhan Corp.’s U.S. offshoot. It is located within the Cambridge Innovation Center (CIC
Celltrion said on Friday that it received marketing authorization from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) for its autoimmune disease treatment, Remsima SC (ingredient: infliximab).Celltrion received marketing authorization for the full range of indications appro
Korean researchers drew attention at the American Society of Clinical Oncology annual meeting, ASCO 2023, by presenting a variety of therapeutic strategies, including immunotherapies, which will contribute to improving the treatment landscape for significant and rare cancers.The Korea Cancer Study G
Shares of VUNO shot up by around 11 percent on Thursday morning after the company announced that its AI-based cardiac arrest prediction medical device, VUNO Med-DeepCARS, has been designated as an innovative medical device by the U.S. FDA, the first in the Korean medical AI industry. As of 11:11 a.m
Samsung Biologics and Pfizer said they signed a $411.3 million long-term agreement for Samsung Biologics to manufacture Pfizer’s pharmaceutical products. The companies did not disclose the duration of the "long-term" contract.The latest contract is Samsung Biologics' largest partnership agreement si
Matica Biotechnology, a U.S. subsidiary of CHA Biotech, unveiled its new MatiMax cell lines at the 2023 BIO International Convention (BIO 2023), hoping that it could boost cell and gene therapy (CGT) CDMO contracts.The new GMP-grade cell lines outperform industry standards and enable rapid growth pe
Kainos Medicine said on Wednesday that the phase 3 clinical trial results of its HIV/AIDS treatment, KM-023 (ingredient: ainuovirine), which demonstrated excellent safety and efficacy was published in one of the world's leading medical journals.KM-023 is a next-generation non-nucleoside reverse tran
CHICAGO, Ill. -- By Kim Yun-mi/Korea Biomedical Review correspondent -- "The ADAURA study is the first global phase 3 trial to demonstrate a statistically significant and clinically meaningful overall survival (OS) benefit with targeted therapy in patients with resected stage 1B to 3A EGFR-mutated n
Celltrion said on Monday that it signed an agreement with U.S.-based biotech, Rani Therapeutics, to develop an oral formulation of RT-105 (ingredient: adalimumab), a treatment for autoimmune diseases.Accordingly, Celltrion will exclusively supply Rani with an oral adalimumab formulation and will hav
CHICAGO, Ill. -- By Kim Yun-mi/Korea Biomedical Review correspondent -- The annual meeting of the American Society of Clinical Oncology (ASCO 2023), the world's largest cancer conference, has successfully returned to full strength following a temporary pause during the Covid-19 pandemic. Packed with
Daewoong Pharmaceutical said on Monday that it terminated the exclusive license agreement with Neurogastrx initially intended for the clinical development and commercialization of Fexuclue (ingredient: fexuprazan) in the U.S. and Canada.Fexuclue is Daewoong Pharmaceutical’s gastroesophageal reflux d
HLB Science, which is developing a next-generation sepsis treatment, said on Friday that it signed a research agreement with NodCure, a company that has the technology to develop microbiome-based therapeutics for metabolic and immune diseases.Through this agreement, HLB Science will conduct joint re
Starting this month, Janssen's psoriasis treatment, Tremfya (ingredient: guselkumab), will be covered by the national health insurance for patients in Korea with palmoplantar pustulosis (PPP) treated with methotrexate or cyclosporine.Previously, Tremfya was only covered for patients with PPP treated
The Ministry of Food and Drug Safety (MFDS) said on Friday that it initiated administrative penalties and recall and destruction procedures against Huons BioPharma for the unauthorized sale of its botulinum toxin (BTX) Liztox Inj. 100 units without obtaining domestic export approval.The penalty incl